CYTK
Price
$58.53Alerts
Change
+$2.35 (+4.18%)
Updated
Nov 11 closing price
Capitalization
7.46B
111 days until earnings call
Intraday BUY SELL Signals
DARE
Price
$0.69Alerts
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
Capitalization
12.62M
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CYTK vs DARE

CYTK vs DARE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CYTK vs. DARE commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and DARE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CYTK with price predictions
Nov 10, 2026

CYTK's RSI Oscillator climbs out of oversold territory

The RSI Indicator for CYTK moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 22 of the 25 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a +4.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in 212 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In 77 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for CYTK turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 48 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

The 50-day moving average for CYTK moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for CYTK entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. CYTK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-43.024) is normal, around the industry mean (3.498). P/E Ratio (-7.436) is within average values for comparable stocks, (-1.193). CYTK's Projected Growth (PEG Ratio) (82.230) is slightly higher than the industry average of (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (128.205) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for DARE with price predictions
Nov 10, 2026

DARE's RSI Oscillator ascending out of oversold territory

The RSI Indicator for DARE moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In 34 of the 38 cases the stock moved higher. This puts the odds of a move higher at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 63 cases where DARE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on DARE as a result. In 65 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for DARE just turned positive on October 30, 2026. Looking at past instances where DARE's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.

Following a +7.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where DARE advanced for three days, in 165 of 219 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for DARE entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-22.504) is normal, around the industry mean (3.498). P/E Ratio (-0.972) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.502) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. DARE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
CYTK vs DARE: Fundamental Ratings
CYTK
DARE
OUTLOOK RATING
1..100
162
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
7
Undervalued
PROFIT vs RISK RATING
1..100
82100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
7588
P/E GROWTH RATING
1..100
149
SEASONALITY SCORE
1..100
5012

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DARE's Valuation (7) in the Biotechnology industry is significantly better than the same rating for CYTK (94). This means that DARE’s stock grew significantly faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as DARE (100). This means that CYTK’s stock grew similarly to DARE’s over the last 12 months.

CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as DARE (100). This means that CYTK’s stock grew similarly to DARE’s over the last 12 months.

CYTK's Price Growth Rating (75) in the Biotechnology industry is in the same range as DARE (88). This means that CYTK’s stock grew similarly to DARE’s over the last 12 months.

DARE's P/E Growth Rating (9) in the Biotechnology industry is in the same range as CYTK (14). This means that DARE’s stock grew similarly to CYTK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKDARE
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
70%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 6 days ago
79%
Bearish Trend 9 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
77%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CYTK: $56.18 vs. DARE: $0.69)
Brand notoriety: CYTK and DARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 118% vs. DARE: 111%
Market capitalization -- CYTK: $7.46B vs. DARE: $12.62M
CYTK [@Biotechnology] is valued at $7.46B. DARE’s [@Biotechnology] market capitalization is $12.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green while DARE’s FA Score has 2 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • DARE’s FA Score: 2 green, 3 red.
According to our system of comparison, DARE is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 4 TA indicator(s) are bullish while DARE’s TA Score has 5 bullish TA indicator(s).

  • CYTK’s TA Score: 4 bullish, 5 bearish.
  • DARE’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, DARE is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а -9.84% price change this week, while DARE (@Biotechnology) price change was +6.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

CYTK is expected to report earnings on Mar 02, 2027.

DARE is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
QLVD35.31N/A
N/A
Northern Trust Developed Markets ex-US Quality Low Volatility ETF (QLVD)
JIRE82.39-0.44
-0.53%
JPMorgan International Research Enhanced Equity ETF (JIRE)
MSSM58.59-0.35
-0.59%
Morgan Stanley Pathway Small-Mid Cap Equity ETF (MSSM)
INVN26.72-0.17
-0.63%
Alger Russell Innovation ETF (INVN)
FPXI60.65-0.59
-0.97%
First Trust International Equity Opportunities ETF (FPXI)